7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one;N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one;N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
• 化学式: C33H28ClN7O3
• 分子量: 606.1
• InChiKey: CMVPZQLKTJVLJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.11
• 重原子数：
  44
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• NANOPARTICLE DELIVERY COMPOSITIONS
  申请人：Midatech Ltd.

  公开号：EP2956119A1

  公开（公告）日：2015-12-23
• [EN] NANOPARTICLE DELIVERY COMPOSITIONS<br/>[FR] COMPOSITION D'ADMINISTRATION DE NANOPARTICULES
  申请人：MIDATECH LTD

  公开号：WO2014125256A1

  公开（公告）日：2014-08-21

  Nanoparticle delivery systems for use in targeting biologically active agents to the central nervous system comprise a composition comprising (a) a nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise a carbohydrate, insulin and/or a glutathione; and (b) the at least one agent to be delivered to the CNS. Methods of treatment and diagnosing CNS disorders utilising the nanoparticle delivery systems and related screening methods are also disclosed.